Literature DB >> 29353731

Evaluating hydrophobic galactonoamidines as transition state analogs for enzymatic β-galactoside hydrolysis.

Jessica B Pickens1, Logan G Mills1, Feng Wang2, Susanne Striegler3.   

Abstract

A spectroscopic examination of six galactonoamidines with inhibition constants and efficacy in the low nanomolar concentration range (Ki = 6-11 nM, IC50 = 12-36 nM) suggested only two of them as putative transition state analogs for the hydrolysis of β-galactosides by β-galactosidase (A. oryzae). A rationale for the experimental results was elaborated using docking and molecular dynamics studies. An analysis of the combined observations reveals several common factors of the compounds suggested as transition state analogs (TSAs): the putative TSAs have a similar orientation in the active site; show conserved positioning of the glycon; display a large number of H-bond interactions toward the catalytically active amino acid residues via their glycon; and exhibit hydrophobic interactions at the outer rim of the active site with small changes of the position and orientation of their respective aglycons.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Galactonoamidines; Hydrophobic loops; Inhibitor; Molecular dynamics; Transition state analogs; β-Galactosidase

Mesh:

Substances:

Year:  2018        PMID: 29353731      PMCID: PMC5857253          DOI: 10.1016/j.bioorg.2018.01.012

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  30 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

Review 3.  Using linear and non-linear regression to fit biochemical data.

Authors:  R J Leatherbarrow
Journal:  Trends Biochem Sci       Date:  1990-12       Impact factor: 13.807

4.  Canonical sampling through velocity rescaling.

Authors:  Giovanni Bussi; Davide Donadio; Michele Parrinello
Journal:  J Chem Phys       Date:  2007-01-07       Impact factor: 3.488

5.  Abnormal cortical lysosomal β-hexosaminidase and β-galactosidase activity at post-synaptic sites during Alzheimer's disease progression.

Authors:  Alessandro Magini; Alice Polchi; Alessandro Tozzi; Brunella Tancini; Michela Tantucci; Lorena Urbanelli; Tiziana Borsello; Paolo Calabresi; Carla Emiliani
Journal:  Int J Biochem Cell Biol       Date:  2014-11-12       Impact factor: 5.085

6.  Structural features of Aspergillus niger β-galactosidase define its activity against glycoside linkages.

Authors:  Agustín Rico-Díaz; Mercedes Ramírez-Escudero; Ángel Vizoso-Vázquez; M Esperanza Cerdán; Manuel Becerra; Julia Sanz-Aparicio
Journal:  FEBS J       Date:  2017-05-02       Impact factor: 5.542

7.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

8.  Phosphonamidates as transition-state analogue inhibitors of thermolysin.

Authors:  P A Bartlett; C K Marlowe
Journal:  Biochemistry       Date:  1983-09-27       Impact factor: 3.162

9.  Solid-phase synthesis and biochemical evaluation of conformationally constrained analogues of deglycobleomycin A5.

Authors:  Ali Cagir; Zhi-Fu Tao; Steven J Sucheck; Sidney M Hecht
Journal:  Bioorg Med Chem       Date:  2003-11-17       Impact factor: 3.641

10.  Arabinoamidine synthesis and its inhibition toward β-glucosidase (sweet almonds) in comparison to a library of galactonoamidines.

Authors:  Jessica B Pickens; Susanne Striegler; Qiu-Hua Fan
Journal:  Bioorg Med Chem       Date:  2016-05-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.